| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
Study cohort comprises samples derived from patients that received treatment on an open-label, non-randomized, non-comparative pilot study of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, with nivolumab in refractory sarcoma at Memorial Sloan Kettering/MD Anderson Cancer Centers (NCT03282344). Patient tumors include a variety of sarcoma subtypes. Samples include whole exome sequencing of tumor/normal pairs, poly-A RNA and TCR sequencing of tumors.
- Study Design:
- Clinical Trial
- Study Type:
- Clinical Trial
- Exome Sequencing
- Multicenter
- RNA Sequencing
- Tumor vs. Matched-Normal
- Total number of consented subjects: 54
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
-
- BioProject
- Sequence Read Archive
- BioSample
- Clinical Trials
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Sarcoma
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigator
- Sandra D'Angelo, MD. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
-
Investigator
- Samuel Singer, MD. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
-
Funding Source
- SPORE in Soft Tissue Sarcoma NIH/NCI P50 CA217694. National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator